Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
Taysha Gene Therapies, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.00, Taysha Gene Therapies, Inc. trades at 236.0x sales and 4.5x book value. Over the last twelve months it generated about $6M of revenue and a net loss of $140M. It runs a gross margin of 89.2%, an operating margin of -2935.4% and a net margin of -2844.6%. It shows return on equity of -51.9%, return on invested capital of -39.0% and a free cash flow yield of -11.1%. On the balance sheet: a debt-to-equity ratio of 0.15 and a current ratio of 18.56. Over the past 52 weeks the share price ranged from $3.46 to $7.30, with a beta of 1.17.
Taysha Gene Therapies, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 15 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.